Sulprostone for preoperative cervical dilatation in primigravidae scheduled for late first trimester termination of pregnancy.
The cervix was primed with intracervical (intramural), i.m. or s.c. injections of Sulprostone in varying doses at various times before termination of late first trimester pregnancy in 170 primigravidae. Intracervical administration of Sulprostone (25-100 micrograms) 14-16 h before surgery required the lowest dosage and had no side effects. However, the highest dose of Sulprostone (100 micrograms) achieved a cervical dilatation to Hegar 7 or more in only 40% of patients. A cervical dilatation of Hegar 7 or more was achieved in 90% of the cases when 350 micrograms of Sulprostone was given i.m. 3-4 h preoperatively.
D000028:Abortion, Induced; D000287:Administration, Topical; D002584:Cervix Uteri; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D013997:Time Factors
D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone